|
End-of-day quote
Nasdaq
2026-09-04
|
5-day change | 1st Jan Change | ||
| 5.320 USD | -1.12% |
|
+7.47% | +3.70% |
| 08-31 | Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80 | MT |
| 08-31 | Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review | MT |
Company Valuation: Alvotech
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 308.8 | 2,486 | 3,048 | 3,991 | 1,606 | 1,899 | - | - |
| Change | - | 705.34% | 22.59% | 30.92% | -59.76% | 18.25% | - | - |
| Enterprise Value (EV) 1 | 308.8 | 3,165 | 3,959 | 5,330 | 2,883 | 2,976 | 2,956 | 2,849 |
| Change | - | 925.01% | 25.11% | 34.63% | -45.92% | 3.22% | -0.66% | -3.63% |
| P/E | -0.8x | -3.85x | -4.72x | -15.2x | 9.5x | 102x | 17.9x | 10.4x |
| PBR | - | -4.41x | -2.8x | -8.59x | -5.22x | -10.2x | -24.6x | 14.3x |
| PEG | - | 0x | 0.72x | 0.2x | -0x | -1.1x | 0x | 0.1x |
| Capitalization / Revenue | 8.4x | 29.9x | 32.6x | 8.11x | 2.73x | 2.88x | 2.45x | 2.1x |
| EV / Revenue | 8.4x | 38.1x | 42.4x | 10.8x | 4.9x | 4.51x | 3.81x | 3.15x |
| EV / EBITDA | - | -9.71x | -12x | 52.8x | 24.8x | 16.1x | 11.2x | 7.94x |
| EV / EBIT | - | -9.13x | -11.2x | 76.5x | 36.9x | 21x | 13.3x | 9.07x |
| EV / FCF | - | -9.04x | -11.5x | -18.3x | -18.7x | -22.7x | 89.6x | 27.4x |
| FCF Yield | - | -11.1% | -8.72% | -5.45% | -5.36% | -4.4% | 1.12% | 3.65% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -12.29 | -2.6 | -2.43 | -0.87 | 0.54 | 0.052 | 0.297 | 0.5107 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 36.77 | 83.03 | 93.38 | 492 | 588.9 | 659.3 | 775.7 | 904.5 |
| EBITDA 1 | - | -326 | -330.6 | 100.9 | 116.1 | 184.4 | 263 | 359 |
| EBIT 1 | - | -346.4 | -354.9 | 69.64 | 78.21 | 141.5 | 222.1 | 314.1 |
| Net income 1 | - | -513.6 | -551.7 | -231.9 | 157.9 | 30.36 | 109.1 | 178.4 |
| Net Debt 1 | - | 678.2 | 911 | 1,340 | 1,277 | 1,077 | 1,057 | 949.9 |
| Reference price 2 | 9.880 | 10.000 | 11.480 | 13.230 | 5.130 | 5.320 | 5.320 | 5.320 |
| Nbr of stocks (in thousands) | 31,250 | 248,650 | 265,530 | 301,640 | 313,019 | 356,912 | - | - |
| Announcement Date | 5/10/22 | 3/1/23 | 3/20/24 | 3/26/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 102.29x | 4.51x | 16.14x | -.--% | 1.9B | |
| 33.15x | 5.95x | 17.82x | 0.98% | 48.93B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.41x | 29.72x | -.--% | 40.73B | |
| 28.42x | 8.6x | 21.8x | 0.4% | 33.52B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 24.24x | 2.11x | 9.11x | 1.11% | 14.67B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 39.87x | 31.68x | 14.06x | 0.28% | 28.79B | |
| Weighted average by Cap. | 27.81x | 47.04x | 12.33x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALVO Stock
- Valuation Alvotech
Select your edition
All financial news and data tailored to specific country editions
